Shanghai Shengyue Biotechnology Co., Ltd-Shuze Scientific Research Research

Shuze Scientific Research

Home page

Overview of the research institute

Overview of the institute

Shanghai Shuze Biotechnology Research Institute is a private research unit engaged in biochemical research in the field of life sciences in China. In 2003, the institute was established on Halei Road in Zhangjiang High tech Park, Pudong, Shanghai. In 2007, it was relocated to No. 539 North Ring Road, Fengxian District, Shanghai, and is located in today's "Oriental Beauty Valley" in Shanghai. Under the leadership of the second director, Lou Xiuyu, Shanghai Shuze Biotechnology Research Institute has overcome the serious shortage of research and development funds in private scientific research units, as well as the easy loss of high-end talents, and achieved remarkable results.

The team successfully developed the "Youth Joy" HGH peptide and "IGF-1 sustained-release tablets" to promote human health and longevity in March 2005; In May 2008, the "Young Station" bovine colostrum active peptide, which promotes the secretion of HGH by the human pituitary gland, was successfully developed; In 2018, with the strong support of a team of scientists led by Professor Guo Li, the "HGHI" series of genetic technology products were successfully developed. Since its establishment for twenty years, the research institute has been conducting research, promotion, and application in the fields of HGH, SOD, and NMN anti-aging. At the same time, he has made significant contributions to the country in genetic engineering technology, earning him a reputation in the field of life science research in China.

Important Development History

Important development and evolution

On January 15th, the 8500 square meter research building and 2700 square meter office building of Shanghai Shuze Biotechnology Research Institute were completed.

On March 12th, the new office building of Shanghai Shuze Biotechnology Research Institute, located in the "Oriental Beauty Valley" of Shanghai, began construction, taking another big step forward.

Relocation to No. 539 North Ring Road, Fengxian District, Shanghai

LouXiuyu cooperates with institutes of cell biology ,Shanghai Institutes for biological sciences Chinese academy of sciences to prepare for the establishment of the Shanghai Shuze Institute of Biotechnology





2021year

2019year

2007year

2003year

Product R&D History

Product Development Experience

2023year

One kind β- The synthesis method of nicotinamide mononucleotide (NMN) has obtained national patent approval (patent number: ZL2020 1 0610156.7)

2021year

The fifth generation product, HGHI active protein amino acid composite powder, has been successfully developed using liposome encapsulation, macromolecule encapsulation, and polymer adsorption sustained-release technology.

2019year

Bioenzyme conversion β- The pilot test of nicotinamide mononucleotide (NMN) has been successful and is currently applying for a national invention patent.

2018year

Successfully developed HGH active protein amino acid composite powder and "Youth Station" active protein peptide using polymer adsorption and sustained-release technology.

2015year

We have successfully developed genetic engineering technology recombinant human superoxide disproportionation cool brand S O D (Guoshijianzi G20150216).

2014year

Immune Enhancement Tablets (Guoshi Jianzi G20141302)

2013year

In 2013, developed a variety of vitamin and mineral tablets that meet the dietary and nutritional balance of Chinese people (Guoshi Jianzi G20130724)

2008year

In May 2008, a "young station" active peptide was successfully developed to promote the secretion of HGH by the human pituitary gland

2005Year

In March 2005, the use of macromolecular parcel technology, which successfully developed the "young music" HGH polypeptide capsule and "IGF-1 slow-release tablet for human health and longevity